|
|
CAF06 |
|
Vaxjo ID |
364 |
|
Vaccine Adjuvant Name |
CAF06 |
|
Adjuvant VO ID |
VO_0005550
|
|
Description |
cationic liposomal adjuvant that induces mixed Th1/Th17 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
surfactant DDA (dimethyldioctadecylammonium bromide) formulated into liposomes |
|
Function |
induced an antigen-specific CD8(+) T-cell response and a humoral response |
| References |
Nordly et al., 2011: Nordly P, Agger EM, Andersen P, Nielsen HM, Foged C. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharmaceutical research. 2011; 28(3); 553-562. [PubMed: 21042837].
Pedersen et al., 2018: Pedersen GK, Andersen P, Christensen D. Immunocorrelates of CAF family adjuvants. Seminars in immunology. 2018; 39; 4-13. [PubMed: 30396811].
|
|
